Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions

Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia

“…Its action is the same as free P G E 1 [12], but it is more stable than free PGE~ to enzymatic inactivation in the body and causes less irritation [12,13,17]. Lipid microspheres may accumulate in the injured portions of vessels [10,11,14,18]. Thus, once the endothelial injury occurs, more lipo-PGE 1 builds up, which may yield excess dilatation of the DA.…”

“…The agent also decreases pulmonary vascular resistance [8,9] therefore, it is also used for the treatment of persistent fetal circulation (PFC) in congenital diaphragmatic hernia [14]. In recent years, lipo-PGE1, lipoid microspheres containing PGE1, has been employed for clinical use [10,[12][13][14]18].…”

Synthesis of Prostaglandin E1 Phosphate Derivatives and Their Encapsulation in Biodegradable Nanoparticles

“…With these points in mind, we developed lipo-PGE 1 , a preparation incorporating PGE 1 into an oil-in-water lipid emulsion (lipid microspheres) consisting of a soybean oil core and lecithin surfactant with a diameter of approximately 200 nm (10)(11)(12). Incorporation of PGE 1 into lipid microspheres protects PGE 1 from inactivation in the lung and enables the selective delivery of PGE 1 to damaged blood vessels, resulting in enhanced therapeutic effects and reduced adverse effects (10,13,14). Lipo-PGE 1 is used clinically in Japan, South Korea and China for systemic administration and exhibits a more potent therapeutic effect for peripheral obstructive vascular diseases than does PGE 1 clathrated in cyclodextrin which is used clinically worldwide (12,15).…”

Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome

“…35,36 Benefits of lipid microspheres preparations are attributed to avoidance of the inactivation of drugs, as well as a favorable uptake by reticuloendothelial systems, including inflammatory cells. 36,37 Mizushima et al 38 demonstrated that radiolabeled lipo-PGE1 accumulated more densely in the vascular wall than did free PGE1, especially in vascular lesions. This indicates that lipo-PGE1 penetrates vascular endothelium and then accumulates in blood vessels to result in augmentation of the pharmacological action of prostaglandin.…”